Effects of cigarette smoking on metabolic activity of lung cancer on baseline 18F-FDG PET/CT

被引:2
作者
Jiang, Maoqing [1 ,2 ]
Guo, Xiuyu [1 ]
Zhang, Xiaohui [1 ]
Gao, Qiaoling [1 ]
Mei, Weiqi [2 ]
Zhang, Jingfeng [3 ]
Zheng, Jianjun [1 ]
机构
[1] Univ Chinese Acad Sci, Hwa Mei Hosp, CT Ctr, Dept PET, Ningbo, Zhejiang, Peoples R China
[2] Univ Chinese Acad Sci, Hwa Mei Hosp, Dept Nucl Med, Ningbo, Zhejiang, Peoples R China
[3] Univ Chinese Acad Sci, Hwa Mei Hosp, Dept Educ, Ningbo, Zhejiang, Peoples R China
来源
PEERJ | 2022年 / 10卷
关键词
Cigarette smoking; Metabolic status; PET/CT; 18F-FDG; Lung cancer; STANDARDIZED UPTAKE VALUE; POSITRON-EMISSION-TOMOGRAPHY; FACTOR-RECEPTOR GENE; NEVER-SMOKERS; PROGNOSTIC VALUE; EGFR MUTATION; SURVIVAL; ADENOCARCINOMA; GEFITINIB; NSCLC;
D O I
10.7717/peerj.13352
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background. Never-smokers with lung cancer usually have a higher survival rate than that of smokers. The high metabolic activity of lung cancer on F-18-2-Fluoro-2deoxyglucose (F-18-FDG) PET/CT generally indicates a poor outcome. However, there is a lack of reports on the association between cigarette smoking and F-18-FDG metabolic activity in patients with lung cancer. In this study, we aimed to investigate the effects of cigarette smoking on metabolic activity of lung cancer on F-18-FDG PET/CT. Materials and Methods. A total of 338 patients (230 males, 108 females; mean age: 66.3, range 34-86) with pathologically diagnosed lung cancer were enrolled from September 2019 to April 2021. All patients underwent baseline F-18-FDG PET/CT and the maximum standard uptake value (SUVmax) of the primary tumor (pSUVmax), lymph node (nSUVmax) and distant metastasis (mSUVmax) were measured. The associations between cigarette smoking status, clinical stage, pathological subtypes and metabolic parameters on F-18-FDG PET/CT were analyzed. Results. Of the 338 patients, cigarette smoking was identified in 153 patients (45.3%) and the remaining 185 (54.7%) were never-smokers. Smoking was found more frequently in males, squamous cell carcinoma (SCC) and stage III-IV diseases. The pSUVmax in smokers was significantly higher than that in never-smokers (t = 3 .386 , P < 0.001), but the nSUVmax and mSUVmax revealed no statistically significant differences (t = 0.399, P = 0.690 and t = 0.057, P = 0.955; respectively). With the increase of cumulative smoking dose, pSUVmax increased significantly (r = 0.217, P < 0.001). In addition, the pSUVmax in patients with stage III-IV was significantly higher than that in stage I-II (t = 8.509, P < 0.001). Smokers showed a higher pSUVmax than never-smokers for patients with stage I-II (t = 3.106, P = 0.002), but not in stage III-IV (t = 0.493, P = 0 .622) . The pSUVmax was significantly different among patients with different pathological subtypes of lung cancer (F = 11.45, P < 0.001), while only the adenocarcinoma (ADC) and SCC groups showed a difference in pSUVmax (t = 6.667, P < 0.001). Smokers with ADC showed a higher pSUVmax when compared to never-smokers, but not in SCC. There were no significant differences of pSUVmax between smokers and never-smokers at stage I-II ADC or SCC and stage III-IV ADC or SCC. Conclusions. This study demonstrated a close association between cigarette smoking and the metabolic activity of lung cancer and suggests that smoking may be a potential risk factor of higher pSUVmax in early lung cancer on F-18-FDG PET/CT.
引用
收藏
页数:17
相关论文
共 37 条
  • [1] Epidemiology of lung cancer - ACCP evidence-based clinical practice guidelines (2nd edition)
    Alberg, Anthony J.
    Ford, Jean G.
    Samet, Jonathan M.
    [J]. CHEST, 2007, 132 (03) : 29S - 55S
  • [2] Armour B. S., 2005, Morbidity and Mortality Weekly Report, V54, P625
  • [3] Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC) -: A systematic review and meta-analysis (MA) by the European lung cancer working party for the IASLC lung cancer staging project
    Berghmans, Thierry
    Dusart, Michele
    Paesmans, Marianne
    Hossein-Foucher, Claude
    Buvat, Irene
    Castaigne, Catherine
    Scherpereel, Arnaud
    Mascaux, Celine
    Moreau, Michel
    Roelandts, Martine
    Alard, Stphane
    Meert, Anne-Pascale
    Patz, Edward F., Jr.
    Lafitte, Jean-Jacques
    Sculier, Jean-Paul
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (01) : 6 - 12
  • [4] FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0
    Boellaard, Ronald
    O'Doherty, Mike J.
    Weber, Wolfgang A.
    Mottaghy, Felix M.
    Lonsdale, Markus N.
    Stroobants, Sigrid G.
    Oyen, Wim J. G.
    Kotzerke, Joerg
    Hoekstra, Otto S.
    Pruim, Jan
    Marsden, Paul K.
    Tatsch, Klaus
    Hoekstra, Corneline J.
    Visser, Eric P.
    Arends, Bertjan
    Verzijlbergen, Fred J.
    Zijlstra, Josee M.
    Comans, Emile F. I.
    Lammertsma, Adriaan A.
    Paans, Anne M.
    Willemsen, Antoon T.
    Beyer, Thomas
    Bockisch, Andreas
    Schaefer-Prokop, Cornelia
    Delbeke, Dominique
    Baum, Richard P.
    Chiti, Arturo
    Krause, Bernd J.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 (01) : 181 - 200
  • [5] SMOKING AND CARCINOMA OF THE LUNG - PRELIMINARY REPORT
    DOLL, R
    HILL, AB
    [J]. BRITISH MEDICAL JOURNAL, 1950, 2 (4682) : 739 - 748
  • [6] The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer
    Ichihara, Shuji
    Toyooka, Shinichi
    Fujiwara, Yoshiro
    Hotta, Katsuyuki
    Shigematsu, Hisayuki
    Tokumo, Masaki
    Soh, Junichi
    Asano, Hiroaki
    Ichimura, Kouichi
    Aoe, Keisuke
    Aoe, Motoi
    Kiura, Katsuyuki
    Shimizu, Kenji
    Date, Hiroshi
    Shimizu, Nobuyoshi
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (06) : 1239 - 1247
  • [7] 18F-fluoro-2-deoxy-glucose uptake predicts clinical outcome in patients with gefitinib-treated non-small cell lung cancer
    Il Na, Im
    Byun, Byung Hyun
    Kang, Hye Jin
    Cheon, Gi Jeong
    Koh, Jae Soo
    Kim, Cheol Hyeon
    Choe, Du Hwan
    Ryoo, Baek-Yeol
    Lee, Jae Cheol
    Lim, Sang Moo
    Yang, Sung Hyun
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (07) : 2036 - 2041
  • [8] Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with non-small-cell lung cancer for gefitinib treatment
    Jida, Masaru
    Toyooka, Shinichi
    Mitsudomi, Tetsuya
    Takano, Toshimi
    Matsuo, Keitaro
    Hotta, Katsuyuki
    Tsukuda, Kazunori
    Kubo, Takafumi
    Yamamoto, Hiromasa
    Yamane, Masaomi
    Oto, Takahiro
    Sano, Yoshifumi
    Kiura, Katsuyuki
    Yatabe, Yasushi
    Ohe, Yuichiro
    Date, Hiroshi
    Miyoshi, Shinichiro
    [J]. CANCER SCIENCE, 2009, 100 (10): : 1931 - 1934
  • [9] Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-small Cell Lung Cancer A Comprehensive Analysis of 26,957 Patients with NSCLC
    Kawaguchi, Tomoya
    Takada, Minoru
    Kubo, Akihito
    Matsumura, Akihide
    Fukai, Shimao
    Tamura, Atsuhisa
    Saito, Ryusei
    Maruyama, Yosihito
    Kawahara, Masaaki
    Ignatius, Sai-Hong
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : 620 - 630
  • [10] Gender, Histology, and Time of Diagnosis Are Important Factors for Prognosis Analysis of 1499 Never-Smokers with Advanced Non-small Cell Lung Cancer in Japan
    Kawaguchi, Tomoya
    Takada, Minoru
    Kubo, Akihito
    Matsumura, Akihide
    Fukai, Shimao
    Tamura, Atsuhisa
    Saito, Ryusei
    Kawahara, Masaaki
    Maruyama, Yosihito
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (07) : 1011 - 1017